Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation

Clin Exp Ophthalmol. 2019 Jul;47(5):638-645. doi: 10.1111/ceo.13453. Epub 2019 Jan 2.

Abstract

Background: Exogenous endophthalmitis is a potential complication of intraocular surgery and frequently results in visual impairment. Current treatment involves administration of intravitreal (IVT) antibiotics with or without vitrectomy surgery. Evidence for the use of adjunctive anti-inflammatory agents is conflicting. We set out to determine if bevacizumab, a humanized monoclonal IgG1 antibody targeted against vascular endothelial growth factor (VEGF), has anti-inflammatory properties in experimental models of Gram-positive and Gram-negative inflammation.

Methods: BALB/c mice were subjected to lipopolysaccharide- (LPS) or peptidoglycan- (PGN) induced ocular inflammation and treated with IVT bevacizumab. Iris microvasculature was imaged 6 hours following irritant/treatment using intravital microscopy (IVM) before the mice were euthanized and the eyes were enucleated immediately post-mortem. Following enucleation, levels of VEGF and 23 cytokines and chemokines (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17, TNF, KC, G-CSF, GM-CSF, Eotaxin, INF-γ, MCP-1, MIP-1α, MIP-1β, RANTES) were quantified using a multiplex assay.

Results: Levels of VEGF were significantly increased during the inflammatory response, triggered by either PGN or LPS. Both the adherence of leukocytes to the iris vascular endothelium and the levels of pro-inflammatory cytokines and chemokines were significantly increased following administration of either irritant. Treatment with bevacizumab decreased levels of leukocyte adherence in LPS-treated eyes, however, not in PGN-treated eyes. Conversely, bevacizumab treatment decreased levels of cytokines and chemokines (TNF, IL-6, MCP-1, MIP-1α, MIP-1β, RANTES, KC) in PGN-treated eyes, however, not in LPS-treated eyes.

Conclusions: Within a 6-hour window bevacizumab had anti-inflammatory actions that were distinct in both Gram-positive (PIU) and Gram-negative (EIU) models, respectively. Given our findings, this would suggest that bevacizumab may have utility as an adjunctive therapy to IVT antibiotics and vitrectomy in the management of exogenous endophthalmitis.

Keywords: bevacizumab; lipopolysaccharide; ocular inflammation; peptidoglycan; vascular endothelial growth factor a.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Bevacizumab / therapeutic use*
  • Cytokines / metabolism
  • Disease Models, Animal
  • Eye Infections, Bacterial / drug therapy*
  • Eye Infections, Bacterial / etiology
  • Eye Infections, Bacterial / metabolism
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / etiology
  • Gram-Negative Bacterial Infections / metabolism
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / etiology
  • Gram-Positive Bacterial Infections / metabolism
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Inflammation / microbiology
  • Intravitreal Injections
  • Lipopolysaccharides
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Peptidoglycan
  • Time Factors
  • Uveitis / drug therapy*
  • Uveitis / metabolism
  • Uveitis / microbiology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Cytokines
  • Lipopolysaccharides
  • Peptidoglycan
  • Vascular Endothelial Growth Factor A
  • lipopolysaccharide, E. coli O26-B6
  • vascular endothelial growth factor A, mouse
  • Bevacizumab

Grants and funding